Total submissions: 3
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Eurofins Ntd Llc |
RCV000592783 | SCV000704773 | uncertain significance | not provided | 2018-02-08 | criteria provided, single submitter | clinical testing | |
Labcorp Genetics |
RCV001867953 | SCV002177727 | uncertain significance | Zellweger spectrum disorders | 2022-08-07 | criteria provided, single submitter | clinical testing | This sequence change replaces isoleucine, which is neutral and non-polar, with threonine, which is neutral and polar, at codon 424 of the PEX1 protein (p.Ile424Thr). This variant is present in population databases (rs201807430, gnomAD 0.02%). This variant has not been reported in the literature in individuals affected with PEX1-related conditions. ClinVar contains an entry for this variant (Variation ID: 499334). Algorithms developed to predict the effect of missense changes on protein structure and function are either unavailable or do not agree on the potential impact of this missense change (SIFT: "Deleterious"; PolyPhen-2: "Possibly Damaging"; Align-GVGD: "Class C0"). In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance. |
Ambry Genetics | RCV004955688 | SCV005468260 | uncertain significance | Inborn genetic diseases | 2024-07-30 | criteria provided, single submitter | clinical testing | The c.1271T>C (p.I424T) alteration is located in exon 6 (coding exon 6) of the PEX1 gene. This alteration results from a T to C substitution at nucleotide position 1271, causing the isoleucine (I) at amino acid position 424 to be replaced by a threonine (T). Based on insufficient or conflicting evidence, the clinical significance of this alteration remains unclear. |